A Study of a New Leishmania Vaccine Candidate ChAd63-KH (Leish2a)
A Phase IIa Safety Study to Assess the Safety and Immunogenicity of a New Leishmania Vaccine Candidate ChAd63-KH
Sponsor: University of Khartoum
A PHASE2 clinical study on Leishmaniasis, Cutaneous, this trial is completed. The trial is conducted by University of Khartoum and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Dec 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Khartoum
- University of York
For direct contact, visit the study record on ClinicalTrials.gov .